Privia Health Group (PRVA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.19
- Estimate
- $0.24
- Surprise
- -22.2%
- Revenue (period 2026-06-30)
- $632.6M
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
Privia Health Group (PRVA) missed the $0.24 estimate with adjusted EPS of $0.19 — a large 22.2% shortfall.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRVA Sell at 6.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -22.2% surprise compares with a +4.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (3.9 < 4.0)
- Value-trap signals (2/5): Material insider selling (27 sells, 0.16% of cap), Negative free cash flow
- Momentum score 4.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.70
- Price target
- $28.32
- Stop
- $20.54
- Upside to target
- +30.5%
- Reward-to-risk
- 3.9:1
The stock trades at 104.7× trailing but 20.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
PRVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $2.81B
- P/E (fwd)
- 20.7
- P/E (ttm)
- 104.7
- 52-week range
- $18.91–$28.82
- Off 52-week high
- 24.7%
- RSI (14)
- 53
- Volume vs avg
- 0.05×
- Score today
- 6.1/10